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Summary Vascular endothelial growth factor (VEGF) is a well known factor that induces angiogenesis. Four isoforms, i.e. VEGF206, 189,
165, and 121, have been identified. We examined the isoform patterns of VEGF mRNA using reverse transcription polymerase chain reaction
(RT-PCR) analysis in 61 colon cancers. All the colon cancers examined expressed VEGF121. The isoform patterns were classified into three
groups: type 1, VEGF 21; type 2, VEGF121 + VEGF165; type 3, VEGFl21 + VEGF165 + VEGF 89. Three ofthe 61 colon cancers examined
showed type 1 expression, 26 showed type 2 expression and 32 showed the type 3 pattern. The patients with liver metastases showed the
type 3 isoform expression pattern at a significantly higher incidence (12 of 16, 75%) than those without liver metastasis (20 of 45, 44%)
(P = 0.036). The type 3 isoform pattern was significantly associated with Ml stage (P = 0.019). The patients with colon cancer and the type 3
isoform pattern showed significantly poor prognosis (P< 0.01, Cox-Mantel). The colon cancers with the type 3 pattern showed a significantly
higher involvement of veins (P= 0.006). These observations suggest thatthe aberranttype 3 expression pattern of VEGF189 mRNA isoforms
is correlated with liver metastasis, M stage, and poor prognosis in colon cancer.
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Many patients with advanced colon cancers die as a result of liver
metastases even after curative surgery. The key properties and
events that lead to metastatic colony formation are not clearly
understood. Many studies have focused on stromal angiogenesis in
connection with distant metastasis of cancers. Basic fibroblastic
growth factor, transforming growth factor-p and tumour necrosis
factor-a are well known as angiogenic factors.
Recently, vascular endothelial growth factor (VEGF) has been
studied as an angiogenic factor (Keck et al, 1989; Leung et al,
1989). VEGF was discovered because ofits ability to increase the
permeability of the microvasculature to circulating macro-
molecules (Senger et al, 1983). VEGF is an endothelial cell-
specific antigen and angiogenic factor in vivo, and this factor plays
an important role in neovascularization of various kinds of
neoplasms. The overexpression of VEGF has been demonstrated
in neoplasms of the colon (Brown et al, 1993; Takahashi et al,
1995), breast (Brown et al, 1995), brain (Berkman et al, 1993),
ovary (Boocock et al, 1995), and liver (Suzuki et al, 1996)
compared with normal tissue (Berse et al, 1992).
Four different isoforms of VEGF transcripts encoding poly-
peptides of206, 189, 165 and 121 amino acids have been reported
to be expressed in human cells (Houck et al, 1991), and these
VEGF isoforms possess different biological activities (Houck et
al, 1992; Park et al, 1993). VEGF121 and VEGF165 are secreted
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in soluble form, whereas the two larger isoforms (VEGF189 and
VEGF206) remain associated with cells because of their stronger
affinities for cell-surface proteoglycans. VEGF121 is not a
heparin-binding protein, while the other isoforms possess heparin-
binding activity (Cohen et al, 1995). The mitogenic activities of
VEGF121 and VEGF165 are inhibited by platelet factor-4
(Gengrinovitch et al, 1995).
VEGF165 is expressed in most tissues (Dvorak et al, 1995), but
the precise expression patterns of other VEGF transcript isoforms
are not well understood. Alternative expression of isoforms of
VEGF mRNA is regulated by cell density in colon cancercell lines
(Koura et al, 1996). The patterns of expression of VEGF mRNA
isoforms are not different between tumour and non-tumour tissues
in the liver (Suzuki et al, 1996). The clinicopathological signifi-
cance of the different patterns of expression of VEGF mRNA
isoforms in colon cancer is not well understood. Thus, we
analysed the correlation between VEGF isoform expression
pattern and clinical features in colon cancers.
MATERIALS AND METHODS
Subjects and tissue samples
The subjects in this study were 61 patients with colon cancer who
underwent surgical resections between October, 1989 and October,
1991, at Tokai University Hospital. All patients were evaluated by
TNM score (UICC, 1978). Patients' characteristics are summa-
rized in Table 1. Surgical specimens were rapidly frozen and
stored at -80°C until analyses. Total cellular RNA was prepared
from frozen specimens (Sambrook et al, 1989).
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Table 1 Patients' characteristics and univariate analysis of the associations
between VEGF isoform pattern and patient or tumour characteristics
Variable Type 1 and type 2 Type 3 P-value
Total
Sex
Male
Female
Age (years)
<60
>60
Histology
Adenocarcinoma
Mucinous carcinoma
v Factor
vi +2
v2 + .
ly Factor
lyl +2
Iy2+<
T Staging
TO, Ti, T2
T3, T4
N staging
NO
Ni, N2, N3
M staging
MO
Ml
Liver metastasis
Yes
No
fit-1 expression
Yes
No
KDR expression
Yes
No
K-ras mutation
Yes
No
29 (47.5)
16 (26.2)
13 (21.3)
13 (21.3)
16 (26.2)
27 (44.3)
2 (3.3)
20 (32.8)
9 (14.8)
12 (19.7)
17 (27.9)
6 (9.8)
23 (37.7)
16 (26.2)
13 (21.3)
25 (41.0)
4 (6.6)
4 (6.6)
25 (41.0)
17 (27.9)
12 (19.7)
23 (37.7)
6 (9.8)
15 (24.6)
14 (22.9)
Exon1-3 4 5 Exon 8 _
VEGF121 - _ bL- 243 bp 4 .V-S-
32 (52.5)
18 (29.5)
14 (23.0)
12 (19.7)
20 (32.8)
31 (50.8)
1 (1.6)
11 (18.0)
21 (34.4)
9 (14.8)
23 (37.7)
6 (9.8)
26 (42.7)
16 (26.2)
16 (26.2)
19 (31.1)
13 (21.3)
12 (19.7)
20 (32.7)
13 (21.3)
19 (31.1)
20 (32.8)
12 (19.7)
12 (19.7)
20 (32.8)
P = 0.917
VEGF165
P= 0.566
P= 0.960
VEGF189
P = 0.006a
VEGF206
P= 0.280
aAberrant VEGF189 expression (type 3) was significantly correlated with the
v factor, Ml stage and liver metastasis of colon cancer (P < 0.05, X2 test).
Numbers in parentheses are percentages.
0
a.
..-
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Figure 1 Primers for detection of the isoforms of VEGF mRNA. Arrows
indicate the sites of primers V-S, V-A, V-S4 and V-A7. PCR with V-S and V-A
gave VEGF121 (243 bp), VEGF165 (375 bp), VEGF189 (447 bp) and
VEGF206 (498 bp) fragments. PCR with V-S4 and V-A7 gave VEGF165,
VEGF189 and VEGF 206 fragments
polymerase (Toyobo, Japan). Blots of products (Zeta-Probe, Bio-
Rad) were hybridized with photochemically labelledprobes (ECL;
Amersham) and exposed to Kodak AR film. The quality of the
RNA was estimated by RT-PCR for ,2-microglobulin.
Histological examination of colon cancer
Colon cancer specimens were fixed with 10% formalin and
embedded with paraffin according to routine procedures.
Histological sections were cut from the centre of each colonic
tumour and stained with haematoxylin and eosin (H & E) as well
as Victoria blue-H & E to define venous invasion of the colonic
wall. Histological examination was independently reviewed by
two pathologists. The degree of venous invasion was classified
into four groups as follows: vO, no venous invasion; vl+, minimal
venous invasion, i.e. one or two foci of venous invasion in the
histological sections; v2+, moderate venous invasion, i.e. three or
four foci of venous invasion; and v3+, severe venous invasion
more than five invasion foci. Also, the degree of lymphatic inva-
sion; lyl+, mild lymphatic invasion; Iy2+, moderate lymphatic
invasion; and ly3 +, severe lymphatic invasion.
RT-PCR analysis to detect VEGF isoform transcripts
We evaluated isoforms of VEGF mRNA by RT-PCR using the
following primers: V-S, 5-AAGCCATCCTGTGTGCCCCT-
GATG-3; V-S4, 5-CGGATCAAACCTCACCAAGGCC-3; V-A,
5-GCGAATTCCTCCTGCCCGGCTCAC-3; V-A7, 5-CTTTCTC-
CGCTCTGAGCAAGGC-3 (Figure 1). Probes (378 bp) were
prepared by PCR amplification with primers V-S and V-A, and
their sequences were confirmed with an automated sequencer
(ABI PRISM 310, PerkinElmer, CA, USA). Reverse transcription
was performed at 42°C for 60 min (1 jg of total cellular RNA;
100pM random primers, Boehringer Mannheim; reverse transcrip-
tase, Gibco). VEGF cDNA fragments were amplifiedby 30 rounds
of PCR consisting of 1 min at 94°C, 1 min at 550C, 2 min at 720C
with a Gene Amp PCR System 9600 (Perkin Elmer) and Taq DNA
Southern and Northern blotting analyses
Blots of cellular DNAs (13 gg) digested with EcoRI (for 20 h at
37°C, Boehringer Mannheim; Nytran, MSI) were hybridized with
32P-labelled VEGF cDNA and exposed to KODAK RP films
for 1 week at -80°C. The blots of total cellular RNA (15 ,ug,
GeneScreen Plus, New England Nuclear) were hybridized with
32P-labelled VEGF cDNA probes (see above). The levels ofVEGF
gene expression were estimated by densitometry (Interactive Build
Analysis System, Zeiss).
Expression of VEGF receptor (fit-1, KDR) andTGF-01
VEGF receptor gene expression (flt-1, KDR) was estimated by
RT-PCR with the following primers:
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Figure 2 VEGF expression in the tumours determined by RT-PCR (primer
set: V-S, V-A). Lane 1, patient no 1, type 2; lane 2, patient no. 4, type 3; lane
3, patient No. 38, type 3; lane 4, patient no. 5, type 1; lane 5, patient no. 26,
type 2; lane 6, patient no. 42, type 2; lane 7, patient no. 45, type 2; lane 8,
patient no. 58, type 2
fltl-S; 5-ATGAGCAGTGTGAGCGGCTCCC-3 (2669-2690);
fltl-A; 5-AAGCTTTCGCTGCTGGTGACGC-3 (3125-3146);
KDR-S, 5-CGTCATGGATCCAGATGAACTCCC-3
(2406-2429); KDR-A, 5-CTTGACGGAATCGTGCC-
CCTTTGG-3 (2813-2836).
Under conditions similar to those described above,TGF-P1
gene expression was also estimated by RT-PCR with the
following primers:
TGF-P1I-S, 5-GCCCTGGACACCAACTATTGC-3 (1679-1699);
TGF[ -1-A, 5-GTTATGCTGGTTGTACAGGGCC-3
(1864-1885).
Activation of c-K-ras oncogene
Point mutations in the c-K-ras oncogene were evaluated by the
enriched PCR method as reported previously (Ando et al, 1991).
We confirmed point mutations in the c-K-ras oncogene by direct
sequence analysis.
Statistical analysis
Differences in survival between subgroups of patients were
compared with the log-rank (Cox-Mantel) test, and survival curves
were plotted according to the method of Kaplan and Meier. The X2
test was applied for comparisons between group frequencies.
RESULTS
VEGF mRNA isoform patterns
All colon cancer specimens expressed VEGF121 (61 out of 61).
The isoform patterns were classified into three groups: type 1,
VEGF121; type 2, VEGF121 + VEGF165; type 3, VEGF121 +
VEGF165 + VEGF189. Three of the 61 colon cancers examined
showed type 1 expression. Twenty-six of the 61 patients showed
type 2 expression, and the remaining 32 showed the type 3 pattern.
None of the tumours examined showed VEGF206 expression.
These isoform patterns of VEGF mRNA were confirmed with two
sets of amprimers to amplify different portions of the VEGF
cDNA (Figure 2 and Figure 3).
Twenty-two of 25 normal colon tissues did not express VEGF-
mRNA. One of the three normal colon specimens expressing
VEGF showed the type 1 isoform VEGF 121, while the other
normal mucosal specimens showed type 3 isoform expression.
Figure 3 VEGF expression in the tumours determined by RT-PCR (primer
set; V-S4, V-A7). Lane 1, patient no. 1, type 2; lane 2, patient no. 4, type 3;
lane 3, patient no. 38, type 3; lane 4, patient no. 60, type 2; lane 5, patient
no. 26, type 2; lane 6, patient no. 42, type 2; lane 7, patient no. 45, type 2;
lane 8, patient no. 58, type 2
Histological features and VEGF mRNA isoform patterns
The colon cancer specimens with type 3 isoform expression
showed significantly higher incidence of venous vascular involve-
ment (v2 + and v3 +) (P = 0.006, X2 test, Table 1). However, there
was no apparent correlation between this isoform expression
pattern and lymphatic vessel involvement. Histological grade of
colon cancer did not show a significant association with the VEGF
isoform pattern (Table 1).
Correlation between VEGF-mRNA isoform and clinical
characteristics
Twelve patients presented with liver metastases at the time ofoper-
ation, and four patients revealed liver metastases during the
follow-up period. Only one patient presented with pulmonary
metastasis at the time of the operation, whereas such metastases
were detected in four patients during the follow-up period.
Twenty-five patients died because of colon cancer during the
follow-up period.
The 32 patients with colon cancers with the type 3 isoform
expression pattern showed significantly poorer prognosis than
the remaining 29 patients with type 1 and 2 transcript patterns
(P < 0.01, Cox-Mantel, Figure 4).
The patients with colon cancers showing the type 3 isoform
expression pattern had a significantly higher incidence (12 out of
32, 37.5%) ofliver metastasis than those (4 out of29, 13.8%) with
type 1 and 2 isoform patterns (P < 0.05, X2 test, Table 1). Twelve of
the 16 (75.0%) patients with hepatic metastatic lesions showed the
type 3 pattern, whereas 20 ofthe 45 patients (44.4%) without liver
metastasis showed this isoform expression pattern. Aberrant
VEGF189 expression (type 3) was significantly correlated with the
MI stage of colon cancer (P < 0.05, X2 test, Table 1). Thirteen of
17 (76.5%) patients at stage TnNnM1 also showed VEGF189
expression, while 19 of 44 (43.2%) patients at stage TnNnMO
expressed this isoform. There was no correlation between VEGF
mRNA isoform pattern and tumour size (T stage) or lymph node
(N stage) status.
VEGF gene expression levels
Northern blotting analyses showed overexpression of VEGF in all
the materials examined (20 out of20). Levels ofVEGF mRNA up-
regulation were varied. Five normal colonic mucosal specimens
showed no detectable expression of the VEGF gene. The expres-
sion levels did not correlate with VEGF isoform pattern. VEGF
mRNA expression level showed no significant correlation with
metastasis, survival period or any other histological factor exam-
ined. Southern blotting analyses showed neither amplification nor
rearrangement ofthe VEGF gene (data not shown).
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Figure 4 Overall survival according to the isoform pattern of VEGF mRNA.
Patients showing type 3 isoform expression had poorer prognosis than those
with type 1 or 2 isoform expression patterns (generalized Cox-Mantel test,
P< 0.01)
Expression of VEGF receptors and TGF-p1
Thirty of the 61 colon cancers examined expressed flt-I mRNA,
and 43 of 61 colon cancers expressed KDR mRNA. VEGF
receptor expression was not significantly correlated with the
VEGF mRNA isoform pattern (Table 1). Six of the 61 patients
showed expression ofTGF-P1 mRNA.
Activation of c-K-ras oncogene
Activation of the c-K-ras oncogene was detected in 27 of the 61
colon cancers examined. Eighteen ofthese 27 (67%) colon cancers
revealed point mutation (GGT -* GAT) at codon 12 ofthe c-K-ras
gene. No homozygous point mutations were detected. Activation
ofthe c-K-ras oncogene was not correlated with the VEGF mRNA
isoform pattern.
DISCUSSION
Many studies have focused on angiogenesis with regard to distant
metastasis of colon cancers. Vascular endothelial growth factor
(VEGF) has been studied as an angiogenic factor (Keck et al,
1989; Leung et al, 1989). We detected VEGF transcripts in all the
primary human colon cancer specimens, while VEGF expression
was detectable in 3 of 25 normal colon tissues by RT-PCR. The
colon cancers generally overexpressed the VEGF gene, whereas
VEGF transcripts were faint in the normal colonic specimens on
Northern blots. A higher incidence of cells expressing VEGF was
reported in gastrointestinal cancer than in the normal mucosa
(Brown et al, 1993). The overexpression of VEGF was also
demonstrated in colon cancers compared with the levels in the
normal colonic mucosa (Takahashi et al, 1995). Our results
support VEGF overexpression in colon cancers.
It is possible that variable amounts of stromal RNA were co-
purified from the tumours in these bulk studies. We established
several colon cancer xenografts of which stromal elements were
replaced by murine tissue and stored the corresponding primary
colon cancer materials. These colon cancer xenografts showed
identical VEGF isoform expression patterns to the primary
tumours. These results indicate that the VEGF mRNA was not
expressed in the stroma but in the tumour cells. Thus, the possible
contamination of stromal RNA did not affect the results.
Four different isoforms of human VEGF have been identified,
all of which arise from alternative splicing of the primary
transcript ofa single gene. We used two sets ofdifferent primers to
analyse the patterns of VEGF isoforms accurately. RT-PCR
analysis was used to confirm the VEGFisoformexpression pattern
in this study. The expression patterns of VEGF isoforms were not
affected by increasing the number of PCR cycles or amount of
template. In this study, all patients with colon cancer expressed
VEGF121, and the majority of patients showed expression of
VEGF165. However, VEGF189 was expressed in around half of
the patients, and no patients showed expression of VEGF165 or
VEGF189 alone. The majority of hepatocellular carcinomas
expressed these isoforms with an abundance of VEGF121 and
VEGF165 (Suzuki et al, 1996). All neoplasms of the central
nervous system also express VEGF121, VEGF165 and VEGF189
(Berkman et al, 1993). A colon cancer cell line expressed these
three isoforms of VEGF mRNA in vitro (Koura et al, 1996).
However, it is not clear what proportion of colon cancers express
these isoforms. The results of this study show that fewer colon
cancers express these aberrant isoforms of VEGF than brain
tumours or hepatocellular carcinomas. We did not observe the
expression ofVEGF206, which was detected in ahuman fetal liver
cDNA library (Houck et al, 1991), in any ofour specimens.
It is not known which factors affect the isoforms of VEGF
mRNA in colon cancers, although all colon cancers showed over-
expression of the VEGF gene compared with normal tissues. In
this study, the VEGF mRNA isoform pattern was not significantly
correlated with the gene expression level. Activation ofthe c-K/H-
ras oncogenes is correlated with VEGF gene overexpression in rat
intestinal cell lines (Rak et al, 1995). We thus examined activation
of the K-ras oncogene in colon cancers. Forty-five percent of the
colon cancers showed activation of the K-ras oncogene, while
there was no correlation between ras oncogene activation and
VEGF isoform pattern. Expression of the VEGF receptor KDR is
correlated withhepatic metastasis in colon cancer(Takahashi etal,
1995). We also examinedtheexpression ofthe VEGFreceptor(flt-
1, KDR) gene, but found no correlation with the VEGF isoform
pattern. Transforming growth factor-p (TGF-[B) was reported to
up-regulate VEGF gene expression (Dolecki et al, 1991), but we
found no correlationbetweenTGF, production and VEGF mRNA
isoforms in colon cancer.
Little is known about the angiogenic properties of the four
different isoforms of VEGF. Among the various isoforms
VEGF189 protein has the strongest binding capacity to extracel-
lular matrix (ECM) components. Endothelial cells cultured on
ECM derived from cells expressing VEGF189 showed markedly
stimulated proliferation (Houck et al, 1992; Park et al, 1993). The
VEGF189 isoform was up-regulated specifically in confluent
cultures of a colon cancer cell line in vitro (Koura etal, 1996), and
it was suggested that this up-regulation of VEGF189 might result
in increased angiogenesis, tumour growth and metastasis. It has
been suggestedthattheoverexpression ofVEGF is associated with
vascularity ofcolon cancer(Takahashi et al, 1995). However, there
were no reports of a clear correlation between VEGF isoform
expression pattern and clinical characteristics ofcolon cancer. We
showed that the type 3 isoformpattern expression (VEGF189) was
significantly correlated with venous involvement in colon cancer.
In this study, we also demonstrated that the aberrant expression of
the VEGF189 isoform was correlated with liver metastasis andMl
stage in colon cancer.
Recent studies have indicated a correlation between up-regula-
tion oftotal VEGF andhepatic metastasis in colon cancer (Warren
et al, 1995). However, the results presented here suggest that it is
important to examine not only the level of VEGF expression but
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also those isoforms that are expressed to discuss prognostic or
malignant features of colon cancer. Examination of the VEGF
mRNA isoform patterns will be helpful in predicting the prognosis
ofpatients with colon cancer.
ABBREVIATIONS
VEGF, vascular endothelial growth factor; RT-PCR, reverse
transcription polymerase chain reaction
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